When planning to give adjuvant nivolumab for esophageal cancer, would you be comfortable with nivolumab with q4 weekly dosing as opposed to q2 weekly dosing?

I generally start with Q2 week dosing - as per the BMS CheckMate 577 protocol - so that I can make sure that there is not any immediate toxicity. In the study, the dosing was Q2 weeks until 16 weeks and then it moved to Q4 weeks. If a patient is doing well, I have moved to Q4 week dosing at 8 weeks ...